Renaissance Technologies
ALGS icon

Renaissance Technologies’s Aligos Therapeutics ALGS Stock Holding History

Renaissance Technologies’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.3K Sell
10,800
-89,650
-89% -$554K ﹤0.01% 3031
2026
Q1 		$746K Buy
100,450
+15,006
+18% +$114K ﹤0.01% 2413
2025
Q4 		$796K Buy
85,444
+30,425
+55% +$287K ﹤0.01% 2380
2025
Q3 		$539K Buy
55,019
+2,475
+5% +$22.6K ﹤0.01% 2756
2025
Q2 		$379K Buy
52,544
+12,968
+33% +$77.6K ﹤0.01% 2967
2025
Q1 		$327K Buy
39,576
+28,133
+246% +$617K ﹤0.01% 2901
2024
Q4 		$456K Sell
11,443
-2,000
-15% -$38.6K ﹤0.01% 2885
2024
Q3 		$116K Sell
13,443
-17,311
-56% -$215K ﹤0.01% 3232
2024
Q2 		$269K Sell
30,754
-1,576
-5% -$27.7K ﹤0.01% 2949
2024
Q1 		$792K Buy
32,330
+12,732
+65% +$254K ﹤0.01% 2632
2023
Q4 		$325K Buy
19,598
+6,744
+52% +$116K ﹤0.01% 2954
2023
Q3 		$240K Sell
12,854
-4,368
-25% -$96.8K ﹤0.01% 3026
2023
Q2 		$418K Sell
17,222
-892
-5% -$23.9K ﹤0.01% 2971
2023
Q1 		$396K Sell
18,114
-3,176
-15% -$121K ﹤0.01% 2995
2022
Q4 		$507K Sell
21,290
-7,934
-27% -$200K ﹤0.01% 2941
2022
Q3 		$804K Sell
29,224
-6,900
-19% -$229K ﹤0.01% 2630
2022
Q2 		$1.09M Buy
36,124
+21,631
+149% +$735K ﹤0.01% 2649
2022
Q1 		$779K Buy
14,493
+12,313
+565% +$986K ﹤0.01% 2887
2021
Q4 		$647K Buy
2,180
+52
+2% +$19K ﹤0.01% 2957
2021
Q3 		$825K Buy
+2,128
New +$842K ﹤0.01% 2654

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Renaissance Technologies's ALGS Position: Q2 2026 in Review

Renaissance Technologies reduced its Aligos Therapeutics (ALGS) stake by 89% in Q2 2026, selling an estimated $554K and leaving 10,800 shares worth $62.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3031.

Renaissance Technologies first reported a position in ALGS in Q3 2021 and has held it in 20 quarters since. The position peaked at $1.09M in Q2 2022. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

  • Renaissance Technologies held 10,800 shares of Aligos Therapeutics worth $62.3K as of Q2 2026.
  • Renaissance Technologies sold 89,650 Aligos Therapeutics shares in Q2 2026, an estimated $554K.
  • Aligos Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #3031 holding.
  • Renaissance Technologies first reported a position in Aligos Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Renaissance Technologies's Aligos Therapeutics position peaked at $1.09M in Q2 2022.
  • 31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.